These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 418518)

  • 21. Influence of cytochalasin B on the shape change induced in platelets by cold.
    White JG; Krumwiede M
    Blood; 1973 Jun; 41(6):823-32. PubMed ID: 4736475
    [No Abstract]   [Full Text] [Related]  

  • 22. Detection of activated feline platelets in platelet-rich plasma by use of fluorescein-labeled antibodies and flow cytometry.
    Welles EG; Bourne C; Tyler JW; Boudreaux MK
    Vet Pathol; 1994 Sep; 31(5):553-60. PubMed ID: 7801433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantification of the morphological reaction of platelets to aggregating agents and of its reversal by aggregation inhibitors.
    Born GV; Dearnley R; Foulks JG; Sharp DE
    J Physiol; 1978 Jul; 280():193-212. PubMed ID: 99512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet prostaglandin production and its implications.
    Smith JB; Ingerman CM; Silver MJ
    Adv Prostaglandin Thromboxane Res; 1976; 2():747-53. PubMed ID: 983875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
    Haslam RJ; Davidson MM; Desjardins JV
    Biochem J; 1978 Oct; 176(1):83-95. PubMed ID: 215136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interrelation of prostaglandin endoperoxide (prostaglandin G2) and cyclic 3',5'-adenosine monophosphate in human blood platelets.
    Salzman EW
    Biochim Biophys Acta; 1977 Aug; 499(1):48-60. PubMed ID: 196670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of dibutyryl cyclic adenosinemonophosphate and prostaglandin E1 on platelet aggregation and shape changes.
    Wang TY; Hussey CV; Garancis JC
    Am J Clin Pathol; 1977 Apr; 67(4):362-7. PubMed ID: 192067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of prostaglandin endoperoxides on platelet ultrastructure.
    Gerrard JM; White JG
    Am J Pathol; 1975 Aug; 80(2):189-202. PubMed ID: 169697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential effects of the thiol-oxidizing agent, diamide, on human platelets.
    Patscheke H; Wörner P
    Thromb Res; 1978 Apr; 12(4):609-18. PubMed ID: 663899
    [No Abstract]   [Full Text] [Related]  

  • 30. Proceedings: Effects of aggregating agents, cytochalasin B (CB) and neuraminidase (N) on the ultrastructure of freeze dried (FD) human blood platelets.
    Davis RB
    Thromb Diath Haemorrh; 1975 Nov; 34(2):568. PubMed ID: 1198451
    [No Abstract]   [Full Text] [Related]  

  • 31. Optical density variations and microscopic observations in the evaluation of platelet shape change and microaggregate formation.
    Kitek A; Breddin K
    Thromb Haemost; 1980 Dec; 44(3):154-8. PubMed ID: 6781096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Movement of sodium into human platelets.
    Sandler WC; Le Breton GC; Feinberg H
    Biochim Biophys Acta; 1980 Aug; 600(2):448-55. PubMed ID: 7407123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet interaction with bacteria. IV. Stimulation of the release reaction.
    Clawson CC; Rao GH; White JG
    Am J Pathol; 1975 Nov; 81(2):411-20. PubMed ID: 811123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of activators and inhibitors on human blood platelets: study by freeze-fracturing technique and electron microscopy.
    Ariad S; Dvilansky A; Nathan I
    Int J Tissue React; 1984; 6(4):311-5. PubMed ID: 6441789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antagonism of prostaglandins I2, E1 and D2 by prostaglandin E2 in human platelets.
    Bonne C; Martin B; Watada M; Regnault F
    Thromb Res; 1981 Jan 1-15; 21(1-2):13-22. PubMed ID: 6262942
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhibition of ADP-induced responses in human platelets by agents elevating the cyclic AMP level: comparison of aggregation and shape change.
    Steen VM; Holmsen H
    Thromb Haemost; 1984 Dec; 52(3):333-5. PubMed ID: 6099615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
    Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
    Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition and reversal of platelet activation by cytochalasin B or colcemid.
    Boyle Kay MM; Fudenberg HH
    Nature; 1973 Aug; 244(5414):288-9. PubMed ID: 4583103
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
    Eggerman TL; Harker LA; Andersen NH; Wilson CH
    Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
    [No Abstract]   [Full Text] [Related]  

  • 40. Preservation of human platelets with prostaglandin E1 during in vitro simulation of cardiopulmonary bypass.
    Addonizio VP; Macarak EJ; Niewiarowski S; Colman RW; Edmunds LH
    Circ Res; 1979 Mar; 44(3):350-7. PubMed ID: 761317
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.